| Renal Cell Carcinoma
Cabometyx vs Bavencio
Side-by-side clinical, coverage, and cost comparison for renal cell carcinoma.Deep comparison between: Cabometyx vs Bavencio with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBavencio has a higher rate of injection site reactions vs Cabometyx based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Bavencio but not Cabometyx, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cabometyx
Bavencio
At A Glance
Oral
Once daily
Tyrosine kinase inhibitor
IV infusion
Every 2 weeks
PD-L1 blocking antibody
Indications
- Renal Cell Carcinoma
- Liver carcinoma
- Well Differentiated Pancreatic Endocrine Neoplasm
- Neuroendocrine Tumors
- Merkel cell carcinoma
- Urothelial Carcinoma
- Renal Cell Carcinoma
Dosing
Renal Cell Carcinoma (single agent) 60 mg orally once daily until disease progression or unacceptable toxicity.
Renal Cell Carcinoma (+ nivolumab) 40 mg orally once daily in combination with nivolumab (240 mg every 2 weeks or 480 mg every 4 weeks, or subcutaneous formulations) until disease progression or unacceptable toxicity.
Liver carcinoma 60 mg orally once daily until disease progression or unacceptable toxicity.
Differentiated Thyroid Cancer, Well Differentiated Pancreatic Endocrine Neoplasm, Neuroendocrine Tumors 60 mg orally once daily for adults and pediatric patients >=40 kg; 40 mg orally once daily for pediatric patients 12 years and older with bodyweight <40 kg, until disease progression or unacceptable toxicity.
Merkel cell carcinoma, Urothelial Carcinoma 800 mg administered as an intravenous infusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity.
Renal Cell Carcinoma 800 mg administered as an intravenous infusion over 60 minutes every 2 weeks in combination with axitinib 5 mg orally twice daily (12 hours apart) with or without food until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=25%) Diarrhea, fatigue, palmar-plantar erythrodysesthesia, hypertension, decreased appetite, nausea, vomiting, weight decreased, constipation, stomatitis, rash, hypothyroidism, musculoskeletal pain.
Serious Hemorrhage, perforations and fistulas, thromboembolic events, hypertensive crisis, cardiac failure, hepatotoxicity, adrenal insufficiency, proteinuria, osteonecrosis of the jaw, reversible posterior leukoencephalopathy syndrome, thyroid dysfunction, hypocalcemia.
Postmarketing Arterial (including aortic) aneurysms, dissections, and rupture.
Most common (>=20%) fatigue, musculoskeletal pain, diarrhea, hypertension, nausea, rash, infusion-related reaction, cough, constipation, mucositis, palmar-plantar erythrodysesthesia, dysphonia, decreased appetite, hypothyroidism, hepatotoxicity, dyspnea, abdominal pain, urinary tract infection, headache
Serious immune-mediated adverse reactions (pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, myocarditis, neurological toxicities), infusion-related reactions, complications of allogeneic HSCT, major adverse cardiovascular events
Postmarketing neutropenia, sclerosing cholangitis
Pharmacology
Cabozantinib is a tyrosine kinase inhibitor that inhibits MET, VEGFR-1/-2/-3, AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, FLT-3, and TIE-2 - receptor tyrosine kinases involved in oncogenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment.
Avelumab is a human IgG1 lambda monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and B7.1 receptors on T cells to restore anti-tumor immune responses; it also induces antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cabometyx
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Bavencio
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Cabometyx
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Bavencio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Cabometyx
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Bavencio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Cabometyx.
No savings programs available for Bavencio.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CabometyxView full Cabometyx profile
BavencioView full Bavencio profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.